Understanding & Approaching the Alzheimer Patients

Authors

  • Lucksana Inklab Christian University of Thailand

Abstract

          Alzheimer disease is the most common form of senile dementia, account for 60-80% of dementia cases. Alois Alzheimer, a German psychiatrist discovered  Alzheimer disease in 1906, so his name was used for the disease.

          The dementia symptoms of  Alzheimer disease gradually worsen over a number of years. In its early stage, memory loss with the physician determination the differential diagnosis from memory lossas naturally aging by medical evaluation  including a physical and neurological exam, mental status testing, blood test, brain scan and microscopic examination of brain tissue. As the symptom is progressing, the mood and personalities of the patients change; confusion, irritability, aggression, depression and emotion. Loss the ability to carry on a conversation, sensation and feeling loss, then loss their ability to respond to the environment. In the  late stage, The patient will loss all their physical functions and die. Alzheimer patients live an average of 8 years after their symptoms become noticeable to others, but survival can range from 4 to 20 years depending on age and health conditions.

          There are 3 hypothesis explaining the causes of Alzheimer disease, first hypothesis based on the depletion of acetylcholine. The second hypothesis based on Amyloid beta accumulation and forming the Amyloid plaques that will obstruct the neuronal signals between neurons. The third hypothesis involved with Tau protein defection, causing neurofibrillary tangles accumulation in the neurons, destructing the neuronal transportation pathway and leading to death of neurons.

          Currently, there is no curative treatment for Alzheimer disease. Drugs are used primarily to slow the progression. The risk for development of Alzheimer disease increase with age, most individuals with the disease are age 65 or older and the developing of Alzheimer disease double every 5 years after age 65. After age 85, the risk reaches nearly 50 percent. Alzheimer association set the diagnostic criteria for Alzheimer disease. The diagnosis requires clinical examination both physical and neurological exam, documented by results of mental status test and the diagnosis can be confirmed only by microscopic examination of tissue obtained from a cerebral biopsy or at autopsy.Caregivers of Alzheimer patients should understand and accept the symptom change in each stage, help their daily living activities, prevent accidents, care for both physical and mental health, concern with regular check-up and the caregivers should also take good care of themselves.

References

นันทิกา ทวีชาชาติ. (2557). ต้นแบบการป้องกันความเสี่ยงในการเกิดโรคสมองเสื่อมอัลไซเมอร์. (พิมพ์ครั้ง ที่ 2). กรุงเทพ : โรงพิมพ์จุฬาลงกรณ์มหาวิทยาลัย.

สำนักงานสถิติแห่งชาติ. (2557). สถิติผู้ป่วยโรคอัลไซเมอร์ในประเทศไทย. [ออนไลน์]. สืบค้นเมื่อวันที่ 21 กรกฏาคม 25557, จาก https://www.nso.go.th.

Berchtold NC,Cotman CW. (1998). “Evolution in the conceptualization of dementia and Alzheimer disease : Greco-Roman period to the 1960 s”. Neurobiol Aging. 19(3) : 173-189.

De Kosky ST, Williamson JD, Fitzpatrick AL, et.al. (2008). “Gingko biloba for Prevention of Dementia”. Journal of the American Medical Association. 300(19) : 2253 - 2262.

Frostl H , Kurz A. (1999). “Clinical features of Alzheimer's disease”. European Archives of Psychiatry and Clinical Neuroscience. 249(6) : 288 - 290.

Galasko D, Schmitt F, Thomas R, Jin S, Bennett D. (2005). “Detailed assessment of activitives of daily living in moderate to severe Alzheimer's disease”. Journal of the International Neuropsychology Society. 11(4) : 446 - 453.

Hashimoto M, Rockenstein E, Crew L, Masliah E. (2003). “Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimaer's and Parkinson's disease”. Neuromolecular Med. 4(1-2) : 21 - 36.

Hebert LE , Scherr PA, Bienias JL, Bennett DA, Evans DA. (2003). “Alzheimer disease in the US population : prevalence estimates using the 2000 census”. Arch Neurol. 60(8) : 1119 - 1122.

Hoenicka J. (2006). “Genes in Alzheimer's disease”. Rev Neurol. 42(5) : 302 - 305.

Molsa PK, Marttila RJ, Rinne UK. (1995). “Long term surrival and predictors of mortality in Alzheimer's disease and multi-infarct dementia”. Acta Neurol Scand. 91(3) : 159 - 164.

Morris MC, Schneider JA, Tangney CC. (2006). “Thoughts on B-vitamins and dementia”. J. Alzheimer Dis. 9(4) : 429 - 433.

Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. (2006). “Mediterranean diet, Alzheimer disease and Vascularmediation”. Arch Neurol. 63(12) : 1700 - 1717.

Small BJ, Gagnon E, Robinson B. (2007). “Early identification of cognitive deficits : preclinical Alzheimer's disease and mild cognitive impairment”. Geriatrics. 62(4) : 19 - 23.

Wada H, Nakajoh K, Satoh-Nakagawa T. (2001). “Risk factors of aspiration pneumonia in Alzheimer's disease patients”. Gerontology. 47(5) : 271 - 276.

Downloads

Published

2014-09-30

Issue

Section

Academic Article